/
PRPO
$24.98+$0.70 (+2.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$41.7M
2M shares
52-week range
$10.60 – $33.63
62% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
2.82%
Moderate
Price (6 mo)
Loading chart…
Change$-46.82
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9M | $3.1M | $6.1M | $8.8M | $9.4M | $15.2M | $16.0M | $24.0M |
| Cost of revenue | $2.6M | $2.9M | $4.9M | $6.5M | $6.9M | $9.2M | $8.4M | $13.3M |
| Gross profit | $225.0K | $219.0K | $1.1M | $2.4M | $2.5M | $6.0M | $7.6M | $10.7M |
| Gross margin | 7.9% | 7.0% | 18.9% | 27.0% | 26.7% | 39.6% | 47.3% | 44.5% |
| R&D | $1.1M | $2.8M | $2.2M | $2.3M | $2.7M | $2.7M | $2.3M | $0 |
| Operating income | −$13.9M | −$11.0M | −$9.1M | −$9.6M | −$12.8M | −$7.6M | −$4.2M | −$1.2M |
| EBITDA | −$8.0M | −$8.2M | −$8.0M | −$7.1M | −$10.6M | −$4.5M | −$2.7M | $1.5M |
| Net income | −$15.7M | −$13.2M | −$10.6M | −$8.6M | −$12.2M | −$5.9M | −$4.3M | −$363.0K |
| Net margin | -548.0% | -423.5% | -174.4% | -96.6% | -129.7% | -38.5% | -26.9% | -1.5% |
| EPS (diluted) | -217.80 | -46.51 | -14.84 | -8.10 | -10.73 | -4.51 | -2.93 | -0.23 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $80M | $27.40 | $27.40–$27.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Precipio, Inc. Common Stock
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
www.precipiodx.com- Employees
- 71
- IPO / List date
- Jul 18, 2000
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds PRPO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 19,300 | $482.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-09-22 | 1-for-20reverse |
| 2019-04-29 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded PRPO yet.
